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Different mutational processes leave characteristic patterns of somatic mutations in
the genome that can be identified as mutational signatures. Determining the contri-
butions of mutational signatures to cancer genomes allows not only to reconstruct
the etiology of somatic mutations, but can also be used for improved tumor classifica-
tion and support therapeutic decisions. We here present the R package yet another
package for signature analysis (YAPSA) to deconvolute the contributions of muta-
tional signatures to tumor genomes. YAPSA provides in-built collections from the
COSMIC and PCAWG SNV signature sets as well as the PCAWG Indel signatures and
employs signature-specific cutoffs to increase sensitivity and specificity. Furthermore,
YAPSA allows to determine 95% confidence intervals for signature exposures, to per-
form constrained stratified signature analyses to obtain enrichment and depletion
patterns of the identified signatures and, when applied to whole exome sequencing
data, to correct for the triplet content of individual target capture kits. With this
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functionality, YAPSA has proved to be a valuable tool for analysis of mutational signa-
tures in molecular tumor boards in a precision oncology context. YAPSA is available
at R/Bioconductor (http://bioconductor.org/packages/3.12/bioc/html/YAPSA.html).
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1 | INTRODUCTION
Mutational signatures are patterns of mutations arising from specific
mutational processes. Point mutations (single nucleotide variants,
SNVs) in their trinucleotide motif context1 have been studied inten-
sively in this regard. Mutational signature analysis can not only inform
about the etiology of mutations,1 but also give insights into tumor
evolution,2 improve diagnosis and patient stratification3 and support
therapy decision-making.4
The de novo identification of mutational signatures depends on
the availability of very large series of cancer whole genome sequenc-
ing (WGS) or whole exome sequencing (WES) data. In an initial
unsupervised de novo analysis of 507 WGS and 6535 WES tumor
samples from 30 different tumor entities, Alexandrov et al. identified
27 mutational signatures.1 An extended analysis of 10 952 WES
samples and 1048 WGS samples across 40 different tumor entities
revealed 30 validated mutational signatures https://cancer.sanger.
ac.uk/cosmic/signatures_v2. Recently, the pan-cancer analysis of
whole genomes (PCAWG) consortium has published two even larger
collections of SNV mutational signatures extracted from 4645 WGS
and 19 184 WES tumor samples from 92 cancer entities computed
by two different non-negative matrix factorization (NMF) algo-
rithms.5 A consensus of 67 signatures, 47 of which are termed “likely
to be real”, between these two collections was proposed (https://
cancer.sanger.ac.uk/cosmic/signatures_v3). Furthermore, the
PCAWG consortium has provided a classification system to group
small insertions and deletions (Indels) into 83 features and has
extracted 17 Indel mutational signatures (https://cancer.sanger.ac.
uk/cosmic/signatures/ID) from the subcohort of 2780 WGS tumor
samples across 37 entities.5
For roughly half of the identified mutational signatures, underly-
ing mutational processes have been assigned.1,5 These may by
grouped into (a) those linked to aging (clock-like signatures, for exam-
ple, spontaneous deamination), (b) those related to the action of
exogenic carcinogens (eg, benzoapyrene from tobacco smoke or UV
light), (c) those related to defects in DNA repair pathways (eg, homol-
ogous recombination repair (HRR) or mismatch repair (MMR)) or
(d) those related to over-activation of physiologically mutagenic
enzymes (APOBEC or AID).1,5
If a consensus set of mutational signatures is already known, de
novo extraction is not necessary. Instead, the contributions of (known)
signatures can be computed in a supervised analysis or fitting of muta-
tional signatures.6-11 This allows to determine mutational signature
contributions in small sample sets and even individual samples,
thereby enabling the use of mutational signatures to improve cancer
diagnosis and as biomarkers for therapy sensitivity and resistance pre-
diction (reviewed in Van Hoeck et al3). However, fitting of mutational
signatures can lead to false negatives (mutational processes in the
studied cohort that are missing in the used signature set) and false
positives (erroneous detection of mutational processes, which have
not been active in the respective samples, possibly due to over-
fitting).12 While the occurrence of false negatives is reduced with the
availability of increasingly comprehensive sets of mutational signa-
tures, false positives can only be avoided by filtering or correction
strategies in the deconvolution process.
The R/Bioconductor package yet another package for signature
analysis (YAPSA) presented herein performs fitting of mutational sig-
natures. It can determine contributions for both SNV and Indel muta-
tional signatures and for both the COSMIC and PCAWG signature
collections. YAPSA employs a filtering strategy with signature-specific
cutoffs to reduce false positive signature calls and thereby increases
specificity and precision. Furthermore, YAPSA provides 95% confi-
dence intervals (CIs) for the determined signature contributions and
offers the possibility to run constrained stratified analysis to find
enrichment and depletion patterns of the identified signatures in sub-
sets of the called somatic mutations.
Precision oncology subjects samples from individual patients to
broad genomic profiling to identify clinically actionable lesions.13-20
YAPSA may be particularly well suited for application in precision
oncology due to its high specificity achieved through signature-
specific cutoffs and to the possibility to assign confidence levels to
signature calling. Since 2015, YAPSA has been used in a registry trial
for younger adults with advanced cancer across histologies and
patients with rare tumors across all age groups.21,22
2 | MATERIALS AND METHODS
2.1 | General setting and nomenclature
In this work, according to a widely used convention, we call the matrix
of the counted occurrences of every feature (in the case of SNV
mutational signatures the features are SNVs in their triplet context) in
every sample the mutational catalog V. It is the aim of the mutational
signature analysis to decompose this mutational catalog V into two
smaller matricesW and H such that
V ≈ W H ð1Þ
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The columns of the matrix W are the mutational signatures and
the columns of the matrix H are the contributions of every signature
to every sample. W is called the signature matrix and H is called the
exposure matrix.
In an unsupervised extraction or de novo analysis of mutational sig-
natures, both W and H are unknown. As opposed to that, when fitting
mutational signatures, W is known and only H is unknown and has to
be determined. We denote the j-th column of V by V(;j), corresponding
to the mutational catalog of sample j. Analogously we denote the j-th
columns of H by H(;j), which is the exposure vector of sample j. Then
the task of finding H can be written as an optimization problem:
min
H ; jð Þℝl
W H ; jð Þ−V ; jð Þ
  8j  1, :::,mf g, ð2Þ
Under the constraint of non-negativity:
H ijð Þ ≥0 8i 1, :::, lf g8j  1, :::,mf g: ð3Þ
The number of samples is m, i is the index over signatures, l is the
number of signatures, and j is the index over samples.
In YAPSA, the task of finding H is accomplished by a family of
functions called LCD() (linear combination decomposition). These
functions run a three-step procedure:
1. a non-negative least squares (NNLS) using the function nnls()
from the R package nnls23 is performed
2. for all signatures, the obtained exposures, that is, the contributions
of the signatures to the overall mutational catalog, are compared
to the respective signature-specific cutoffs, and only those signa-
tures for which the exposures are higher than the respective opti-
mal signature-specific cutoffs are kept
3. The NNLS procedure is re-run with only the remaining signatures.
4. After having computed the exposures, the user can in addition com-
pute 95% CIs by using the functions variateExp() (for SNV muta-
tional signatures) or confidence_indel_only_calculation()
(for Indel mutational signatures).
For a given cohort, fitting of mutational signatures can be performed
at cohort-wide or per-sample level. In a cohort-wide analysis, the NNLS is
applied to the whole mutational catalog (i.e., the whole matrix V with as
many columns as there are samples in the cohort) simultaneously, whereas
in a per-sample analysis, the mutational catalog is split into the different
columns (the individual patients) and the NNLS is applied to the different
columns separately. In YAPSA, the function LCD_complex_
cutoff_combined() performs both analyses and the user can access
the results of these two complementary analyses separately.
2.2 | Definition of features and signatures
For an analysis of mutational signatures, the mutations are grouped
into categories or features.
2.2.1 | SNV signatures
For SNV mutational signatures, these features are determined by the
nucleotide exchange and the surrounding triplet motif context resulting
in 96 features.1 Using lists of SNV variant calls, in YAPSA the SNV
mutational catalog is assembled by the functions create_mutation_
catalogue_from_df() or create_mutation_catalogue_
from_VR(), which use the functions mutationContext() and
motifMatrix() from the bioconductor package SomaticSignatures.24
2.2.2 | Indel signatures
According to the classification provided by the PCAWG consortium,
Indels are categorized into 83 features in 16 groups.5
• Groups 1 and 2: Deletions of 1 bp C/(G) or T/(A): features are clas-
sified by the repetitive context in which the deletion occurs: 1, 2,
3, 4, 5, or larger than or equal to 6 times the same nucleotide.
• Groups 3 and 4: Insertions of 1 bp C/(G) or T/(A): features are clas-
sified by the repetitive context in which the insertion occurs: 0, 1,
2, 3, 4, or larger than or equal to 5 times the same nucleotide. Here
zero represents an inserted motif in a sequence context where it
was not present before.
• Groups 5 to 8: Deletions of 2 bps, 3 bps, and 4 bps or more than or
equal to 5 bps: features are classified by the repetitive context in
which the deletion occurs: 1, 2, 3, 4, 5 or larger than or equal to
6 times the same deleted motif.
• Groups 9 to 12: Insertions of 2 bps, 3 bps, and 4 bps or more than
or equal to 5 bps: features are classified by the repetitive context
in which the insertion occurs: 0, 1, 2, 3, 4 or larger than or equal to
5 times the same inserted motif. Here zero represents an inserted
motif in a sequence context where it was not present before.
• Groups 13 to 16: Deletions of 2 bps, 3 bps, 4 bps or more than or
equal to 5 bps with microhomology at the breakpoints: features are
defined by the loss of a motif in a partially receptive context of 1 bp,
2 bps, 3 bps, 4 bps or more than or equal to 5 bps either 50 or 30 of
the deletion.
Using the above nomenclature, for Indel mutational signatures, the
mutational catalog V has 83 rows. In YAPSA, the categorization and
counting of Indel mutations and the generation of an Indel mutational
catalog is performed by the function create_indel_mutation_
catalogue_from_df(). The evaluation of microhomology for attri-
bution of a given Indel to Groups 13 to 16 is performed by the function
matchPattern() from the R package Biostrings.25
2.3 | Signature-specific cutoffs
YAPSA provides optimal signature-specific cutoffs in order to filter
the signatures (step 2 in Section 3.1) identified by an initial NNLS
computation (step 1 in Section 3.1).
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These optimal signature-specific cutoffs were trained by an opti-
mizing procedure using a modified Receiver Operating Characteristic
(ROC) analysis implemented in the R package ROCR.26 The objective
of the ROC was to maximize the overlap of the signatures identified
by the YAPSA analysis in its filtering step with the signatures identi-
fied in the original de novo NMF analysis of the respective data sets
(Alexandrov et al., 20131 for COSMIC SNV signatures and Alexandrov
et al., 20205 for PCAWG signatures).
For COSMIC SNV signature analysis, data was downloaded from
ftp://ftp.sanger.ac.uk/pub/cancer/AlexandrovEtAl/somatic_mutation_
data/ on November 4, 2015. From every entity-specific subdirectory
of this URL, files with the suffix “_clean_somatic_mutations_for_sig-
nature_analysis.txt”, which contain the somatic SNV variant calls, were
downloaded. The reference information which signature is present in
which entity was extracted from the matrix displayed in the figure avail-
able at https://cancer.sanger.ac.uk/signatures_v2/matrix.png.
For PCAWG SNV and Indel signature analysis, data was down-
loaded from https://www.synapse.org/#!Synapse:syn11726601/files/
on October 9, 2019. Somatic variant calls were downloaded from the
subfolder structure “Input_Data_PCAWG7_23K_Spectra_DB/ Muta-
tion Catalogs – Spectra of Individual Tumors”. The reference informa-
tion per sample was downloaded from the subfolder structure
“Signatures_in_Samples/SP_Signatures_in_Samples/”.
2.4 | Confidence intervals
YAPSA uses the concept of profile likelihoods, which has been devel-
oped for modeling ordinary differential equations (ODEs),27 to com-
pute CIs for the exposures to mutational signatures. This is carried out
by a multi-step procedure:
1. In YAPSA, when performing an analysis of mutational signatures with
functions from the LCD() family, the signatures present in the data
to be analyzed are determined in a filtering step (cf. Sections “4.
Results” and “3.1 General Setting and Nomenclature”). For such a
solution of equation (Equation (2) with exposures to a determined
subset of l signatures { W ; ind1ð Þ , …, W ; indlð Þ }, the distribution of the
residuals is determined, and then log-likelihoods are computed by
the function variateExp(). In detail, this is performed as follows:
for a given sample v, let R(; v) denote the v-th column of the matrix of
residuals R = W H−V. Let pdf() denote the probability distribution
function of this vector of residuals. In YAPSA the default for pdf() is
set to be a normal distribution with identical mean and SD as R(; v).
Alternatively, the user can also specify another pdf(). The YAPSA







2. We call this the initial model of the data. When computing the CI
for the exposure Huv to a given signature W(; u) in a sample v (using
the nomenclature defined above to denote the u-th column of the
matrix W), this exposure is perturbed, that is, ., Huv!Huv + δ0uv . Here,
δ0uv is the starting value for an iterative procedure (cf. below) and by
default is set to δ0uv = 0:4.
3. Then the exposures to the remaining l-1 signatures are com-
puted again by NNLS:
min
H 1,:::,u−1,u +1,:::,l;vð Þℝ
l−1
W ;1,:::,u−1,u+1,:::lð Þ H 1,:::,u−1,u+1,:::,l;vð Þ


−V 1,:::,u−1,u+1,:::l;vð Þk+CÞ: ð5Þ
3. Where C = W ;uð Þ  Huj + δ0uv
 
−Vuv
 . That leads to an alternative
model of the data. The degrees of freedom of the alternative
model are l-1, that is, one less than those of the initial model.
Analogously to the initial model of the data, the log-likelihood
LogLik#v is computed from the distribution of the residuals of this alter-
native model. Finally, a likelihood ratio test is computed using the log-





2. Then, using the R function pchisq(), a P value for this pertur-
bation δ0uv . The perturbations δ
0
uv may not necessarily correspond to
two-sided 95% CIs, but instead to intervals relating to the computed
P values of the likelihood ratio test. Therefore the Gauss-Newton
method (function newtonsys() in the R package pracma28) is used
to approximate actual 95% CIs.
If the Gauss-Newton method does not converge, the starting
value for the perturbation is adjusted by δ0uv ! δ0uv 2 and steps (2) to
(5) are re-run. If δ0uv reaches a value ≥10, this outer iteration is stopped
and no confidence interval can be computed.
2.5 | Application to WES data
WGS and WES differ in the frequency of occurrence of different
k-mers. According to the concept underlying SNV mutational
signatures,1,5 the triplet (or 3-mer) context of an SNV is used for
categorization of the mutations, leading to 96 different catego-
ries or features. The relative occurrence of these 96 different
features differs between WGS and WES. More precisely, let nWGSX
denote the occurrence of feature X in the whole genome and nWESX






to be the ratio of these two counts. These ratios are not identical for
all features, that is, .,
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9X,Y   : qWGS,WESX ≠qWGS,WESY , ð8Þ
Where F denotes the feature space. It is thus crutial to compute qWGS,WESX
for all features X and to correct for these differences. These correc-
tions can be applied either to the signatures, converting them to “exome
signatures”, or the inverse corrections can be applied to the mutational
catalogs. In YAPSA, we opt for the second alternative, as this keeps the
function calls simple, analogous, and very similar for analyses of both
WES andWGS data. Detailed information can be found in a vignette ded-
icated to this topic: https://www.bioconductor.org/packages/release/
bioc/vignettes/YAPSA/inst/doc/vignette_exomes.html
2.6 | Stratified analysis of mutational signatures
YAPSA performs stratified analysis of mutational signatures with the
constraints that (a) only those signatures, which have been detected
in the entire set, may be used in the deconvolutions of the strata and
(b) the sum of the exposures of a given sample over all strata must
equal to the exposures of this sample in the unstratified analysis. A
stratified analysis of mutational signatures starts by assigning the
mutations to the different strata and building separate mutational cat-
alogs Vk for these strata. The strata have to be provided by the user
based on external criteria, for example, mutation density, replication
timing, or chromatin states. The strata have to be exclusive, that is,
one mutation cannot be in more than one stratum simultaneously.
The constrained stratified analysis of mutational signatures is then
performed by the function SMC() (Stratification of the Mutational




W Hkjð Þ−Vkjð Þ

 8j,k: ð9Þ





Where H is defined as a solution to the unstratified optimization prob-
lem in equation (Equation (2) and underlies the constraint of non-neg-
ativity, that is, H is a solution computed by LCD().
Naturally, the mutational catalogs of the strata have to sum up to





j is the index over samples, i is the index over signatures, l is the
number of signatures, k is the index over strata, and s is the number of
strata. Equation (Equation (11) reflects the additivity of the stratified
mutational catalogs Vk.
The SMC procedure can also be applied when the unstratified
analysis was performed by another strategy, for example, an
unsupervised de novo analysis or extraction of mutational signa-
tures using NMF. Let ~H denote the exposures of this preceding other
analysis. SMC() then solves the task described by equation
(Equation 9) with a slight difference in the additional constraint:
Xs
k =1
Hk = ~H: ð12Þ
Applying SMC() that way, the initial LCD() decomposition of the
unstratified mutational catalog is omitted and its result replaced by
the exposures of the preceding other analysis.
Further information about stratified analyses of mutational signa-
tures can be found in the corresponding vignette: https://
bioconductor.org/packages/3.12/bioc/vignettes/YAPSA/inst/doc/
vignette_stratifiedAnalysis.html
2.7 | External data
For the data used to generate Figure 1, we refer to the Supplemen-
tary Information Section “3 External data”. In this work, the func-
tionality of the software package YAPSA is also demonstrated on
an ovarian cancer data set.29 Data was downloaded on the
4 June 2020 from https://dcc.icgc.org/api/v1/download?fn=/current/
Projects/OV-AU/simple_somatic_mutation.open.OV-AU.tsv.gz. Only
those samples with more than 25 SNVs and more than 20 Indels
were kept for analysis. The whole analysis used to generate
Figures 2–5 and Supplementary Figures 4-6 as well as all numeric
values for this cohort are provided in the supplementary files
Code_for_figure_generation.Rmd (R markdown) and Code_for_
figure_generation.html (compiled report).
2.8 | Processing of samples from the precision
oncology program MASTER
Two samples presented in this work underwent paired-end WGS
(2 × 151 bp) on a HiSeq X instrument (Illumina, San Diego, Califor-
nia) in the framework of the MASTER (Molecularly Aided Stratifi-
cation for Tumor Eradication Research) program of NCT
Heidelberg/Dresden and the German Cancer Consortium is a reg-
istry trial for younger adults with advanced cancer across histolo-
gies and patients with rare tumors across age groups.21,22 Library
preparation was performed with the TruSeq Nano Library Prepara-
tion Kit (Illumina). Alignment with BWA mem, small variant calling,
and calling of somatic copy number aberrations (sCNAs) with
ACEseq30 were performed as described earlier.4,31,32 Somatic SNV
(case1_somaticSnvs.vcf, case2_somaticSnvs.vcf ) and somatic Indel
(case1_somaticIndels.vcf, case2_somaticIndels.vcf ) variant calls
required for reproducibility of the analysis of mutational signatures
as well as segment information obtained from sCNA calling
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F IGURE 1 Functionalities of YAPSA. A, Contributions of mutational signatures (H) are computed for given mutational catalog (V) and
signatures (W) by a multi-step procedure (central flow diagram). Results are visualized as (stacked) barplot; subgroup (SG) information can be used
to pre-sort the samples. B, Stratification of the mutational catalog showing enrichment and depletion patterns of mutational signatures. The
mutational catalog is decomposed into different strata (V1,… Vk) and with known signatures,W the task is to compute a collection of exposure
matrices (H1,… Hk) under constraints. On the right, the y-axis represents normalized contributions of the different signatures in the respective
strata. Error bars: SE of the mean (SEM). SG1, SG2: subgroup 1 or 2. SNV, single nucleotide variants; YAPSA, yet another package for signature
analysis
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(case1_segments.csv, case2_segments.csv) required for the repro-
ducibility of the computation of genomic instability (cf. below) are
provided as supplementary files.
2.9 | Quantification of genomic instability
As described previously,4 genomic instability was assessed using the
Loss-Of-Heterozygosity-Homologous-Recombination-Deficiency
(LOH-HRD) score33-35 and the number of large-scale state transitions
(LSTs).36 Both measures rely on analysis and calling of sCNAs followed
by a reduction of oversegmentation due to technical noise by smooth-
ing of the copy number profiles. Small segments, that are segments
smaller than 3 Mbp, were processed as follows: (i) among the neigh-
boring segments, the one more similar with respect to total and allele-
specific copy number states was determined, and then (ii) the small
segment was merged with the more similar neighbor. The LOH-HRD
score corresponds to the number of subchromosomal segments with
loss of heterozygosity larger than 15 Mbp.33 Using the same smooth-
ing step as the calculation of the LOH-HRD score, LSTs are defined to
be switches between segments of different copy number states larger
than 10 Mbp but smaller than entire chromosome arms.36
F IGURE 2 Cohort-wide analysis of an ovarian cancer cohort with PCAWG SNV signatures. Top panel: absolute exposures; the y-axis displays
the number of SNVs explained by the respective mutational signatures. Middle panel: normalized exposures. Bottom panel: absolute exposures
with 95% CIs; the y-axis displays the number of SNVs explained by the respective mutational signatures. Samples in all panels are ordered on the
x-axis by decreasing SNV mutational load. SNV, single nucleotide variants
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3 | RESULTS
YAPSA performs fitting of mutational signatures in a four-step pro-
cedure (flow chart at the center of Figure 1A): (a) NNLS
decomposition of the mutational catalogue with the provided sig-
natures; (b) filtering out those signatures which have contributions
less than signature-specific cutoffs (provided in the package);
(c) rerun an NNLS with only those signatures left after filtering;
F IGURE 3 Per-sample analysis of an ovarian cancer cohort (same as in Figure 2) with PCAWG SNV signatures. Top panel: absolute
exposures; the y-axis displays the number of SNVs explained by the respective mutational signatures. Middle panel: normalized exposures.
Bottom panel: absolute exposures with 95% CIs; the y-axis displays the number of SNVs explained by the respective mutational signatures.
Samples in all panels are ordered on the x-axis by decreasing SNV mutational load. SNV, single nucleotide variants
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and (d) compute CIs. YAPSA furthermore provides functionality to
correct for different trinucleotide content and can therefore be
used to analyze mutation calls from WES. Several detailed
vignettes provide additional information and examples on the
usage of YAPSA, starting with https://bioconductor.org/packages/
3.12/bioc/vignettes/YAPSA/inst/doc/YAPSA.html. In this work,
we demonstrate the application of YAPSA for fitting mutational
signatures to a publicly available dataset of ovarian cancer.29 We
show how the identification of specific mutational signatures can
serve as biomarker for HRR deficiency and can help predict sensi-
tivity to PARP inhibition. We furthermore show instructive exam-
ples of the application of YAPSA in the MASTER precision
oncology program.21,22
3.1 | Different sets of mutational signatures
YAPSA provides different collections of signatures for mutational signa-
ture analysis: (a) COSMIC SNV signatures (referred to as COSMIC V2 sig-
natures at https://cancer.sanger.ac.uk/cosmic/signatures_v2), (b) PCAWG
SNV signatures (referred to as COSMIC V3 signatures at https://cancer.
sanger.ac.uk/cosmic/signatures_v3), and (c) PCAWG Indel signatures
(https://cancer.sanger.ac.uk/cosmic/signatures/ID). The patterns underly-
ing these signatures are stored as data frames in the software package.
To unambiguously identify the used signature set, in YAPSA we denomi-
nate the COSMIC SNV signatures as AC1 - AC30 (as abbreviation for
Alexandrov COSMIC), the PCAWG SNV signature as SBS1 - SBS67, and
the PCAWG Indel signatures ID1-ID17. The command
F IGURE 4 Cohort-wide analysis of an ovarian cancer cohort with PCAWG Indel signatures. Top panel: absolute exposures; the y-axis
displays the number of Indels explained by the respective mutational signatures. Middle panel: normalized exposures. Bottom panel: absolute
exposures with 95% CIs; the y-axis displays the number of SNVs explained by the respective mutational signatures. Samples in all panels are
ordered on the x-axis by decreasing Indel mutational load. SNV, single nucleotide variants
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data (sigs)
loads the COSMIC V2 SNV signatures to the R workspace, whereas
data (sigs_pcawg)
loads the PCAWG SNV and Indel signatures to the R workspace.
Further information and details can be found in the vignettes pro-




3.2 | Signature-specific cutoffs
To enable highly specific fitting of mutational signatures, YAPSA pro-
vides signature-specific cutoffs for all provided signature sets. These
are threshold values trained individually for each signature based on
the same data from which the respective signature sets had been
extracted1,5 by a modified ROC analysis using the R package ROCR.26
In a modified ROC analysis, a cost function is defined by specify-
ing costs punishing for false negative and false positive findings sepa-
rately. In the implementation of the package ROCR,26 the cost
function is unambiguously defined by the ratio of the cost for a false
negative finding divided by the cost for a false positive finding, which
in the following we call the costfactor:
costfactor =
cost for false negative findings
cost for false positive findings
ð13Þ
The absolute values of the costs for false negative and false posi-
tive findings have no effect on the shape of the cost function; this
shape and hence the minimum of the cost function depend only on
the value of costfactor. YAPSA provides sets of optimal signature-
specific cutoffs for a range of values of costfactor (for the COSMIC
SNV and PCAWG Indel signatures, costfactor was varied in the range
[1,… 10], for the PCAWG SNV signatures, costfactor was varied in the
range [1,… 15]).
For the different values of costfactor, the total number of false
attributions was computed (sum of false positive and false negative
identifications of signatures). In YAPSA, we chose that costfactor to be
optimal for which the total number of false attributions is minimal.
Using this criterion, the optimal costfactor for COSMIC SNV signatures
was 6, the optimal costfactor for PCAWG SNV signatures was 10, and
the optimal costfactor for PCAWG Indel signatures was 3.
Individual ROC analyses were performed for every signature in
the different sets of signatures. Supplementary Figure 1 illustrates the
cost functions in the ROC analyses for the COSMIC SNV signatures,
Supplementary Figure 2 illustrates the cost functions for the PCAWG
SNV signatures, and Supplementary Figure 3 the cost functions for
the PCAWG Indel signatures for the respective chosen optimal values
of costfactor. The global minimum of the cost function, indicated by
vertical red lines in all these figures, defines the optimal signature-
specific cutoff value. These values are displayed in Tables 1-3.
For the clock-like mutational signatures AC1 and AC5 as well as
SBS1 and SBS5, optimal cutoffs were set to be zero, as they can be
expected to be true positives in all analyses and all cohorts.
In YAPSA, the values for these signature-specific cutoffs are
included in the R package. After having loaded the package to the R
workspace, these cutoff values are accessible to the user by executing
the commands:
data (cutoffs)
for COSMIC SNV mutational signatures or
F IGURE 5 Stratified analyses of mutational signatures with enrichment and depletion patterns. The mutational catalog is decomposed into
different strata of mutation density (high, intermediate, and background, for details see main text “1.1. Stratification of the mutational catalog”).
The ovarian cancer data set was analyzed twice: once using the COSMIC V2 SNV, signatures (left panel) and once using the PCAWG SNV
signatures (right panel). The y-axis represents normalized contributions of the different signatures in the respective strata. Some signatures
(including the APOBEC-related signatures AC2 and SBS2) are enriched in regions of high mutation density, some (including the aging-related
signatures AC1, SBS1, AC5 and SBS5) are depleted in regions of high mutation density. Error bars: SEM. SNV, single nucleotide variants
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data (cutoffs_pcawg)
for PCAWG SNV and Indel mutational signatures.
Further information and details can be found in the corresponding
vignette: http://bioconductor.org/packages/3.12/bioc/vignettes/
YAPSA/inst/doc/vignette_signature_specific_cutoffs.html
Fitting of mutational signatures is only feasible if the data to be
analyzed has enough mutations for the NNLS deconvolution to yield
reliable results. Especially in the case of Indels, we thus recommend to
only use YAPSA for an analysis with PCAWG Indel mutational signa-
tures with WGS data. As the Indel Signature ID15 was not determined
through NMF based on WGS data, no signature-specific cutoff could
be computed for ID15; this signature is therefore not displayed in
Supplementary Figure 3 and in Table 3.
For the ovarian cancer data set,29 cohort-wide fitting of muta-
tional signatures with YAPSA was performed with all three available
sets of mutational signatures with the respective sets of signature-
specific cutoffs. The results are show in Figure 2 for the PCAWG
SNV signatures, in Figure 4 for the PCAWG Indel signatures and in
Supplementary Figure 4 for the COSMIC V2 signatures. In these
cohort-wide analyses, signatures associated with aging (AC1 and
AC5 in COSMIC V2 SNV signatures as well as SBS1 and SBS5 in
PCAWG SNV signatures), APOBEC enzymes (AC2 and AC13 in
COSMIC V2 SNV signatures as well as SBS2 and SBS13 in PCAWG
SNV signatures), HRR deficiency (AC3 in COSMIC V2, SBS3 in
PCAWG SNV, as well as ID6 and ID8 in PCAWG Indel signatures),
mismatch repair deficiency (MMR) (AC6 in COSMIC V2 SNV signa-
tures as well as ID1 and ID2 in PCAWG SNV signatures), and expo-
sure to reactive oxygen species (SBS18 in PCAWG SNV signatures)
were identified. Furthermore, the analyses detected presence of
mutational signatures for which the underlying mutational processes
are unknown: SBS40 in PCAWG SNV signatures as well as ID5 and
ID9 in PCAWG Indel signatures (Figures 2-3 and Supplementary
Figure 4).
In accordance with the design of the signature-specific cutoffs,
the signatures identified using the YAPSA algorithm showed very
high overlap and consistency with those signatures identified in
the original NMF-based signature extraction, cf. Alexandrov et al.
2020.5
The ovarian cancer data set29 was also analyzed at per-sample
level (Figure 3 for the PCAWG SNV signatures, Supplementary Fig-
ure 5 for the COSMIC V2 SNV signatures and Supplementary Fig-
ure 6 for the PCAWG Indel signatures). All signatures identified in
the cohort-wide analysis were recovered in the per-sample analy-
sis. In addition to these, several signatures were identified at small
frequencies exclusively in the per-sample analysis (Supplementary
Information Section “1.1 Cohort-wide and per-sample analyses of
mutational signatures“). All of these additional and exclusive signa-
tures together accounted for small fractions of all exposures in the
cohort: 22321.38/666947 = 3.35% for the PCAWG SNV signa-
tures, 114 513.2/666947 = 17.17% for the COSMIC V2 SNV sig-
natures and 1708.969/38754 = 4.41% for the PCAWG Indel
signatures.
3.3 | Confidence intervals
CIs are computed using the concept of profile likelihood.27 A detailed
vignette about the computation of CIs can be found at http://
bioconductor.org/packages/3.12/bioc/vignettes/YAPSA/inst/doc/
vignette_confidenceIntervals.html.
For the ovarian cancer data set, CIs for exposures were calculated
and displayed for the PCAWG SNV signatures (Figures 2 and 3), the
PCAWG Indel signatures (Figure 4 and Supplementary Figure 6) and
the COSMIC V2 signatures (Supplementary Figures 4 and 5). Detec-
tion of a signature in the mutational catalog of a sample was termed
to be “high confidence” if (i) the signature was detected at all and
(ii) CI computed for the exposure to this signature in the respective
sample excludes zero. As opposed to that, if the CI of the exposure to
a signature in a sample included zero, we termed this signature to be
detected with “low confidence” in the respective sample.
According to this nomenclature, signatures associated with aging
were detected in all samples of the cohort and this calling had high con-
fidence in almost all samples of the cohort: out of 70 samples,
65 (92.86%) and 5 (7.14%) had high and low confidence calls for AC1,
respectively, 70 (100%) and 0 (0%) had high and low confidence calls
for SBS1, 64 (91.43%) and 6 (8.57%) had high and low confidence calls
for AC5, and 50 (71.43%), 16 (22.86%) and 4 (5.71%) had high confi-
dence calls, low confidence calls or no detection for SBS5, respectively.
The fraction of high confidence calls for the signatures associated
with APOBEC activity was lower: 58 (82.86%) and 12 (17.14%) samples
had high and low confidence calls for AC2, 42 (60.00%), 24 (34.29%)
and 4 (5.71%) samples had high confidence calls, low confidence calls or
no detection for SBS2, 36 (51.43%), 24 (34.29%) and 10 (14.28%) sam-
ples had high confidence calls, low confidence calls or no detection for
AC13 and 50 (71.43%), 14 (20.00%) and 6 (8.57%) samples had high
confidence calls, low confidence calls or no detection for SBS13,
respectively. For some signatures, including AC6 (associated with MMR
deficiency), hardly any detection was high confidence: 1 (1.43%),
31 (44.29%) and 38 (54.28%) samples had high confidence calls, low
confidence calls or no detection for AC6, respectively.
Of note, the CIs for the exposures to signatures associated with HRR
deficiency (SBS3 in PCAWG SNV, AC3 in COSMIC V2 and ID6 and ID8
in PCAWG Indel signatures) revealed high fractions of high confidence
calls: 70 (100%) samples had high confidence calls for AC3, 65 (92.86%)
and 5 (7.14%) samples had high and low confidence calls for SBS3,
64 (91.43%) and 6 (8.57%) samples had high and low confidence calls for
ID6, and 52 (74.28%), 17 (24.29%) and 1 (1.43%) samples had high confi-
dence calls, low confidence calls or no detection for ID8, respectively.
The presence of this mutational mechanism in this cohort can thus be
detected with high confidence in this ovarian cancer cohort.
3.4 | Application of YAPSA to WES data
As WGS and WES differ in the frequency of occurrence of different k-
mers, these differences have to be corrected for. In YAPSA, this is per-
formed with the function normalizeMotifs_otherRownames().
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Of note, WES can be performed with different target capture kits.
As these cover different genomic regions, the correction factors may
vary between the different target capture kits. For target capture-
specific correction, that is, for a given target capture kit A, correction
factors qWGS,WESAX for all features have to be computed, and YAPSA
allows for this specificity. As detailed below, correction factors for
nine different target capture kits and one correction factor directly
derived from the gene model GENCODE 19 applied to the human ref-
erence genome hs37d5 are stored in YAPSA. The available correction














are provided. When correcting, for example, for the triplet content in
the target capture kit Agilent SureSelect all exon, the function
normalizeMotifs_otherRownames()
targetCapture <- " AgilentSureSelectAllExon "




can be called as follows:
More information and a detailed example of application of YAPSA
to WES data can be found in a dedicated vignette:
https://www.bioconductor.org/packages/release/bioc/vignettes/
YAPSA/inst/doc/vignette_exomes.html
3.5 | Stratification of the mutational catalog
To further characterize the properties of mutational processes, SNVs
can be assigned into different categories (termed strata in the follow-
ing), for which signature enrichment or depletion patterns can be
computed. Performing separate analyses of mutational signatures on
the strata individually can be error-prone: As the statistical power of a
stratum is always lower than the power of the entire set of mutations,
separate analyses are prone to yield signature calls in individual strata
which include signatures that have not been present in the analysis of
the entire set of mutations. Such errors can be avoided by a con-
strained stratified analysis.
The strata have to be exclusive, that is, every SNV must be in
exactly one stratum. Examples for strata are genomic regions with
low, intermediate or high mutation density, genomic regions with
early or late replication timing, and clonal or subclonal mutations. This
is also of particular interest when studying localized mutational pro-
cesses (cf. Maura et al.12). YAPSA provides the function SMC
(Stratified analysis of mutational signatures) to solve the stratified
optimization problem (Methods Section “3.5 Stratification of the
mutational catalogue”). Stratified analyses of mutational signatures
are also covered in a dedicated vignette: http://bioconductor.org/
packages/3.12/bioc/vignettes/YAPSA/inst/doc/vignette_
stratifiedAnalysis.html
For the ovarian cancer data set, we performed a stratification of
all SNVs by mutation density. SNVs with intermutation distance ≤1
kbp were assigned to a stratum of high mutation density, those with
1 kbp < intermutation distance ≤100 kbp were assigned to a stratum
of intermediate mutation density, and those with intermutation
density > 100 kbp were assigned to a stratum called background.
In both analyses with COSMIC V2 and PCAWG SNV signatures,
the signatures associated with APOBEC enzyme activity, AC2 and
SBS2, showed high enrichment in the stratum of high mutation den-
sity (AC2, Kruskal-Wallis [KW] test, multiple testing correction
TABLE 1 Optimal absolute signature-specific cutoff values for COSMIC SNV mutational signatures in WGS data for a costfactor of 6
Cost factor AC1 AC2 AC3 AC4 AC5 AC6 AC7 AC8 AC9
6 0 0.010459 0.081941 0.017540 0 0.001549 0.040133 0.242755 0.115171
AC10 AC11 AC12 AC13 AC14 AC15 AC16 AC17 AC18
6 0.010084 0.099249 0.2106201 0.007877 0.144306 0.037960 0.3674349 0.002648 0.332539
AC19 AC20 AC21 AC22 AC23 AC24 AC25 AC26 AC27
6 0.115645 0.123503 0.164026 0.031022 0.0333866 0.032402 0.016119 0.093352 0.009320
AC28 AC29 AC30
6 0.056164 0.059362 0.059153
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according to Benjamini and Hochberg: pKW = 4.11*10
−9, SBS2:
pKW = 6.16*10
−8), whereas signature SBS13 showed a still significant,
but less pronounced enrichment (pKW = 3.88*10
−2) and signature
AC13 showed only a trend (pKW = 3.43*10
−1). Complementarily, the
aging signatures were depleted in the stratum of mutations with high
mutation density (AC1: pKW = 6.12*10
−26, AC5: pKW = 1.94*10
−8,
SBS1: pKW = 7.37*10
−29, SBS5: pKW = 3.41*10
−22).
Enrichment and depletion patterns for signatures associated with
HRR deficiency showed an enriched in the stratum of SNVs with high
mutation density in the analysis with COSMIC V2 signatures (AC3:
pKW = 2.19*10
−7) and a trend in the analysis with PCAWG SNV signa-
tures (SBS3: pKW = 1.54*10
−1).
3.6 | Mutational signatures in precision oncology
YAPSA has been used for analysis of mutational signatures in the Molecu-
lar Tumor Board (MTB) of the MASTER program21,22 since 2015. Here,
we present two cases that were analyzed in this framework.
Case1 (Figure 6A-C) was a woman with uterine leiomyosarcoma
and a pathogenic frameshift deletion in BRCA2 (Figure 6B). A tumor
specimen was subjected to WGS in October 2017. A total of 10 866
somatic SNVs and 926 somatic Indels were identified. This case was
characterized by the HRR defect signatures AC3 (explaining 4108 or
37.8% of the somatic SNVs), SBS3 (explaining 3557 or 32.7% of the
somatic SNVs) and ID6 (explaining 392 or 42.4% of the somatic
Indels) when fitting mutational signatures with YAPSA (Figure 6A). All
these signatures were detected with high confidence (confidence
interval excluding zero, Supplementary Table 1). This result matched
the finding of increased genomic instability as evidenced by an LOH-
HRD score33 of 23 and 20 LSTs36 detected in this triploid sample
(Figure 6C). These observations were in line with a germline loss-of-
function mutation in BRCA2. PARP inhibition alone or in combination
may be a therapeutic option for this patient.
Case2 (Figure 6D-E) was a woman with a neuroendocrine neo-
plasm, which was subjected to WGS in January 2020. Neither
germline nor somatic mutations in genes associated with the HRR
pathway were identified (Figure 6E). Furthermore, fitting of muta-
tional signatures with YAPSA did not identify AC3, SBS3, ID6, or ID8
(Figure 6D, Supplementary Table 2). LOH-HRD33 score and the num-
ber of LSTs36 were zero (even though the tetraploid genome did
exhibit whole chromosome sCNAs, but these are excluded in the com-
putation of LOH-HRD and LSTs, Figure 6F). No arguments for the use
of PARP inhibitors were found in this patient.
These two cases illustrate the congruence between mutational sig-
natures and the quantification of genomic instability by LOH-HRD
scores and the number of LSTs. Furthermore, the signature analyses
with the different sets of mutational signatures are consistent between
each other with respect to the detection of HRR-associated signatures.
4 | DISCUSSION
YAPSA is a user-friendly R/Bioconductor package for fitting muta-
tional signatures using SNV and Indel signatures from the COSMIC or
PCAWG signature sets. It uses optimal signature-specific cutoffs to
TABLE 2 Optimal signature-specific cutoff values for PCAWG SNV mutational signatures for a costfactor of 10. Cutoffs are valid for the
analysis of both WGS and WES data. For the clock-like mutational signatures SBS1 and SBS5, optimal cutoffs are set to be zero, as they are true
positives in all analyses and all cohorts
Cost factor SBS1 SBS2 SBS3 SBS4 SBS5 SBS6 SBS7a SBS7b SBS7c
10 0 0.013323 0.001706 0.081066 0 0.21938 0.107568 0.097096 0.010685
SBS7d SBS8 SBS9 SBS10a SBS10b SBS11 SBS12 SBS13 SBS14
10 0.017561 0.25758 0.123529 0.085963 0.056244 0.124596 0.173822 0.011157 0.082277
SBS15 SBS16 SBS17a SBS17b SBS18 SBS19 SBS20 SBS21 SBS22
10 0.062881 0.328003 0.02977 0.031387 0.005704 0.193317 0.11269 0.174782 0.129109
SBS23 SBS24 SBS25 SBS26 SBS28 SBS29 SBS30 SBS31 SBS32
10 0.137645 0.158176 0.307735 0.246075 0.131058 0.109774 0.147923 0.164218 0.243039
SBS33 SBS34 SBS35 SBS36 SBS37 SBS38 SBS39 SBS40 SBS41
10 0.169249 0.170554 0.128734 0.155968 0.235212 0.101551 0.374672 0 0.163599
SBS42 SBS44
10 0.138322 0.158954
TABLE 3 Optimal signature specific cutoff values for PCAWG Indel mutational signatures for a costfactor of three. Cutoffs are valid for the
analysis of WGS data. For signatures ID1 and ID2, optimal cutoffs are set to be zero, as they are true positives in all analyses and all cohorts
Cost factor ID1 ID2 ID3 ID4 ID5 ID6 ID7 ID8 ID9
3 0 0 0.068509 0.159711 0.021578 0.064558 0.290663 0.049468 0.069298
ID10 ID11 ID12 ID13 ID14 ID16 ID17
3 0.179891 0.049493 0.097596 0.127275 0.077038 0.317817 0.158396
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reduce false positive calls and provides CIs as a measure of the uncer-
tainty of determined signature contributions. A functionality for strati-
fied analyses of mutational signatures enables the investigation of
enrichment and depletion patterns in subsets of mutations. Together
with additional functionalities and various visualization capabilities,
this makes YAPSA a comprehensive package to analyze activities of
mutational processes in cancer cohorts of any size, including individ-
ual patient samples.
When applied to an ovarian cancer dataset,5,29 this functionality
recovered mutational mechanisms established to be active in this can-
cer type, reflected by aging signatures, signatures associated with
APOBEC enzyme activity, and signatures associated with HRR
F IGURE 6 Exemplary cases from the NCT/DKTK MTB. A, B, and C: Case1, a woman with uterine leiomyosarcoma and a germline BRCA2
frameshift deletion; D, E, and F,: Case2, a woman with a neuroendocrine neoplasm without mutations in genes of the HRR pathway. A, and D,
display the results of the fitting of mutational signatures with YAPSA; B, and E, highlight clinical and germline information; C, and F, show copy
number plots. Note that whole chromosome events contribute neither to the LOH-HRD score nor to the number of LSTs. HRR, homologous
recombination repair; LSTs, large scale state transitions; LOH-HRD, loss-of-heterozygosity-homologous-recombination-deficiency; YAPSA, yet
another package for signature analysis
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defects.1,5,29 Using the concept of signature-specific cutoffs and
thereby increasing specificity in signature analysis, YAPSA lead to the
detection of these mutational mechanisms consistently across differ-
ent sets of mutational signatures: the COSMIC V2 and PCAWG SNV
signatures as well as PCAWG Indel signature sets. In addition to the
sole detection of signatures and the computation of the respective
exposures, the possibility to assess the confidence of the detection is
of particular use when using mutational signatures for treatment
recommendation.
When applied to a whole cohort, fitting of mutational signatures
can be performed cohort-wide or at per-sample level. The two
methods are complementary. A cohort-wide analysis, on one hand,
identifies mutational signatures and reveals mutational mechanisms
active in the whole cohort with high specificity. The per-sample analy-
sis, on the other hand, is more sensitive and can capture additional
processes active in a single sample, which may have been diluted in
the cohort-wide analysis. However, the per-sample analysis is less
robust to technical noise, is less specific, and may lead to false positive
calls. When applied to the example of the ovarian cancer cohort,29 the
per-sample analysis recovered all signatures identified in the cohort-
wide analysis. Furthermore, in this data set, the contribution of signa-
tures identified exclusively in the per-sample analysis and not in the
cohort-wide analysis was rather small (3.35% for the PCAWG SNV
signatures, 17.17% for the COSMIC V2 SNV signatures and 4.41% for
the PCAWG Indel signatures). These figures capture both the amount
of technical noise and the biological heterogeneity of the samples. A
detailed computation of the respective contributions of these two
sources of variation may only be possible by large scale benchmarks
in future research. Of note, in a setting where the mutational load per
sample is very low, per-sample analyses may not be feasible and
cohort-wide analyses may be the only meaningful alternative.
As shown previously, some mutational signatures may be used as
biomarkers.12,37,38 This is particularly well established for signatures
associated with deficiency in HRR,39,40 that is, signatures AC3, SBS3
and/or ID6 and ID8. Deficiency in HRR might represent a suitable tar-
get for therapeutic intervention using agents, either alone or in combi-
nation, that are preferentially toxic to HRR-incompetent cells, such as
PARP inhibitors, platinum derivatives, or trabectedin.41 Primarily in
BRCA1/2-deficient epithelial cancers, notably breast, ovarian, and
prostate cancer, the concept of “BRCAness” was introduced to char-
acterize an endo-phenotype with various imprints of the DNA repair
defect on the genome, including genomic scars and genomic instabil-
ity.33,36,42,43 Especially in ovarian cancer, BRCAness is frequent and
reflects an established synthetic lethal relationship with pharmaco-
logic PARP inhibition44,45 - leading to the latter class of drugs being
approved for treatment in this entity.46-49 The detection of the HRR-
associated signatures AC3, SBS3, ID6 and ID8 in the ovarian cancer
cohort in this work is in line with this.
Fitting mutational signatures, when used as a detection tool for
HRR-associated signatures (AC3, SBS3, ID6 and ID8), represents a
biomarker which is complementary to the detection of genomic scars
and/or causative mutations in genes of the HRR pathway. Using this
concept, we and others have identified BRCAness in various other
entities, for example, osteosarcoma,50,51 leiomyosarcoma,52 in which
efficacy of PARP1 inhibition has been shown in vitro52 and in preclini-
cal models,53 or chordoma.4 Furthermore, data from a phase 1b trial
of olaparib and trabectedin in unselected patients with relapsed bone
and soft-tissue sarcoma suggest that this treatment might be effective
in subgroups of these entities.54 Additional clinical benefit from sensi-
tive and specific biomarkers of HRR-deficiency may potentially be
obtained by using immune checkpoint blockade in HRR-deficient
tumors and/or combining it with PARP inhibition.55-57
HRR-associated signatures have also been detected in samples
from cancer patients who had been exposed to ionizing radiation,
exemplified in chordomas4 as well as in meningiomas.58,59 Even
though the imprint of ionizing radiation in cancer is not well
understood,60 using YAPSA, comparison of a cohort of low-dose radi-
ation induced meningiomas with a cohort of sporadic meningiomas
revealed that in sporadic meningiomas, BRCAness was associated
with potential causing mutations in genes associated with homolo-
gous recombination repair, whereas in low-dose radiation induced
meningiomas, this was not the case.59 In addition, an enrichment of
the HRR-associated signature AC3 in the vicinity of (potentially
radiation-induced) breakpoints of structural variants was found only
in low-dose radiation induced meningiomas, arguing in favor of AC3
being linked to an exhausted capacity of HRR at the loci of radiation-
induced breakpoints.59 This demonstrates how the functionality of
YAPSA to perform stratified analyses of mutational signatures can be
used to reveal biologically relevant enrichment and depletion
patterns.
Highly precise determination of mutational signature contribu-
tions is particularly useful in precision oncology programs that employ
broad genomic profiling to identify targetable lesions in cancer
patients who have exhausted standard therapy options.13-20 As men-
tioned earlier, the MASTER program is a multicenter registry trial for
patients with rare tumors and for younger adults with advanced can-
cer across all entities.21,22 With its functionality of signature-specific
cutoffs and the possibility to indicate confidence measures for signa-
ture calls, YAPSA has proved to be a valuable tool for fitting muta-
tional signatures in this precision oncology context.4,52,61-63 To date,
more than 2000 patients have been analyzed with YAPSA.
In summary, YAPSA is a tool for fitting mutational signatures with
various unique features: signature-specific cutoffs reduce false posi-
tive calls, CIs are a measure of uncertainty in the detection of signa-
tures in a patient or cohort, and stratified analyses of mutational
signatures yield enrichment and depletion patterns of signature expo-
sures in subsets of the detected mutations, thereby enabling the inter-
pretation of underlying mutational mechanisms.
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DATA AVAILABILITY STATEMENT
External data: For the data used to generate Figure 1, we refer to the
Supplementary Information section “3 External data”. In this work, the
functionality of the software package YAPSA is also demonstrated on
an ovarian cancer data set29. Data was downloaded on the 4th of June
2020 from https://dcc.icgc.org/api/v1/download?fn=/current/Projects/
OV-AU/simple_somatic_mutation.open.OV-AU.tsv.gz. Only those sam-
ples with more than 25 SNVs and more than 20 Indels were kept for
analysis. The whole analysis used to generate Figures 2 - 5 and Supple-
mentary Figures 4 - 6 as well as all numeric values for this cohort are
provided in the supplementary files Code_for_figure_generation.Rmd
(R markdown) and Code_for_figure_generation.html (compiled report).
Processing of samples from the precision oncology program MASTER:
Two samples presented in this work underwent paired-end WGS
(2 × 151 bp) on a HiSeq X instrument (Illumina, San Diego, California) in
the framework of the MASTER program. Library preparation was per-
formed with the TruSeq Nano Library Preparation Kit (Illumina). Align-
ment with BWA mem, small variant calling and calling of somatic copy
number aberrations (sCNAs) with ACEseq30 were performed as
described earlier4,31,32. Somatic SNV (case1_somaticSnvs.vcf,
case2_somaticSnvs.vcf) and somatic Indel (case1_somaticIndels.vcf,
case2_somaticIndels.vcf) variant calls required for reproducibility of the
analysis of mutational signatures as well as segment information
obtained from sCNA calling (case1_segments.csv, case2_segments.csv)
required for the reproducibility of the computation of genomic instabil-
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